Search
BG-777
go.drugbank.com/drugs/DB05839ExperimentalBG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Inolimomab
go.drugbank.com/drugs/DB15628InvestigationalInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease.
ARX201
go.drugbank.com/drugs/DB05082InvestigationalARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol
Velafermin
go.drugbank.com/drugs/DB06493InvestigationalVelafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated
CPG 10101
go.drugbank.com/drugs/DB05530InvestigationalCPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalIt occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. … Human interferon omega 1 (IFN-omega 1 = IFN-alpha II1) is a recently discovered protein structurally related to IFN-alpha and -beta.
Bevasiranib
go.drugbank.com/drugs/DB06642InvestigationalBevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalPF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.
HNM01
go.drugbank.com/drugs/DB06531ExperimentalThe drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.